CHAMPIONS ONCOLOGY, INC.
For the period ended Aug 27, 2026. Filed Aug 28, 2026.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Aug 27, 2026 · Filed Aug 28, 2026
Contents
Director Compensation
The following table summarizes the compensation paid to directors, other than compensation paid to directors who are also named executive officers and whose compensation as executive officers is reflected in the Summary Compensation Table in the Executive Compensation section of this Proxy Statement, for the fiscal year ended April 30, 2026.
| Name · Fees Earned orPaid in cash ($) · Stock awards($) · Option awards ($) (2) · All othercompensation($) · Total ($) | ||||||
|---|---|---|---|---|---|---|
| Joel Ackerman | — | — | 98,226 | 98,226 | ||
| Philip Breitfeld (3) | 35,000 | — | 51,402 | — | 86,402 | |
| Daniel Mendelson | 40,000 | — | 55,225 | — | 95,225 | |
| David Sidransky | 12,000 | — | 69,890 | — | 81,890 | |
| Scott R. Tobin | — | — | 94,898 | — | 94,898 | |
| Brian Alexander (3) | — | — | 15,764 | — | 15,764 | |
| Ronnie Morris (1) | 75,000 | — | — | — | 75,000 | |
| Robert Brainin (1) | 10,000 | — | 30,622 | — | 40,622 | |
(1)Ronnie Morris and Robert Brainin were named executive officers for a portion of the fiscal year ended April 30, 2026, whose executive compensation is set forth in the Summary Compensation Table and related disclosure in the “Executive Compensation” section of this Proxy Statement.
(2)Included in the Option Awards column is the grant date fair value of stock option grants, calculated in accordance with FASB ASC Topic 718.
(3)On March 24, 2026, Dr. Breitfeld resigned from the Board and he was replaced by Dr. Alexander.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.